ADC Therapeutics’ Zynlonta (loncastuximab tesirine-lpyl) Receives the US FDA’s Approval for the Treatment of R/R Diffuse Large B-Cell Lymphoma

 ADC Therapeutics’ Zynlonta (loncastuximab tesirine-lpyl) Receives the US FDA’s Approval for the Treatment of R/R Diffuse Large B-Cell Lymphoma

Shots:

  • The approval is based on data from the P-II LOTIS-2 trial involves assessing Zynlonta in adults with r/r DLBCL following two or more prior lines of systemic therapy
  • Results: ORR (48.3%); CRR (24.1), PR (24.1%), and mDoR in 70 responders (10.3mos.) with a median time to response of 1.3 mos. The therapy will be commercially available in the US imminently
  • Zynlonta is the 1st CD19-targeted ADC approved as a monothx. for adult patients with r/r DLBCL. The company has launched the patient support program to provide financial assistance, education, and other resources for patients who are prescribed the therapy

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: ADC Therapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post